Drugnews

How much has Akeso received from Summit?

By June 30, 2026, Summit had paid Akeso $515 million in cumulative upfront consideration under Akeso’s original ivonescimab license and its 2024 territory expansion, including cash and shares. The July 23, 2026 filing also disclosed up to $4.555 billion in potential regulatory and sales milestones; those conditional amounts should not be counted as money already received.

Updated

License consideration in US dollars; royalties excluded
MeasureReported resultBasis
Original upfront consideration$500 millionPaid; includes cash and shares
2024 expansion upfront$15 millionPaid for additional territories
Cumulative upfront consideration$515 millionOriginal plus expansion; not all cash
Potential remaining milestonesUp to $4.555 billionConditional regulatory and sales milestones

Ivonescimab after the FDA letter

On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.

November 17, 2026 analysis

Sources

Read the full analysis

FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026